G1 Therapeutics
G1 Therapeutics is a commercial-stage biopharmaceutical company that develops COSELA (trilaciclib), an FDA-approved CDK4/6 inhibitor providing myeloprotection for chemotherapy-treated extensive-stage small cell lung cancer patients. The company serves U.S. oncologists and cancer treatment centers, and is a subsidiary of Denmark-based Pharmacosmos Group.
- Company typePrivate
- Founded2008
- HeadquartersTriangle, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What G1 Therapeutics does
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, that develops and markets small-molecule oncology therapies. The company's flagship product, COSELA (trilaciclib), is an FDA-approved intravenous CDK4/6 inhibitor administered prior to chemotherapy to provide myeloprotection, reducing the incidence of chemotherapy-induced myelosuppression (neutropenia, anemia, thrombocytopenia) in adult patients with extensive-stage small cell lung cancer (ES-SCLC). The underlying mechanism transiently halts hematopoietic stem cell division during cytotoxic treatment, protecting bone marrow across multiple lineages without compromising anti-tumor efficacy, and the drug additionally modulates T-cell function to enhance immunotherapy responses.
G1 Therapeutics generated revenue from a single revenue stream, the sale of COSELA to U.S. oncology healthcare providers, reaching customers through specialty pharmacy distribution, hospital outpatient infusion centers, and a field sales and medical science liaison team engaging oncologists, hematologists, and community oncology practices. Pricing is set through standard healthcare channels, insurance, and pharmacy benefit managers. Beyond the approved ES-SCLC indication, trilaciclib has been evaluated in Phase 2 and Phase 3 trials for metastatic triple-negative breast cancer (mTNBC), bladder cancer/urothelial carcinoma, and combinations with sacituzumab govitecan and immune checkpoint inhibitors, with results published at ASCO, SABCS, ESMO, and SITC.
In August 2024, the company was acquired by Denmark-based Pharmacosmos Group for approximately $405 million in cash, becoming a subsidiary of Pharmacosmos Therapeutics and exiting public markets after a 2017 IPO on NASDAQ under the ticker GTHX. The company employs 51-100 people, operates from Research Triangle Park, and is now positioned within a larger oncology supportive care platform with stated intent to expand U.S. market presence.
G1 Therapeutics firmographics
Firmographics- Name
- G1 Therapeutics
- Legal name
- G1 Therapeutics, Inc.
- Website
- https://g1therapeutics.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- G1 Therapeutics is a commercial-stage biopharmaceutical company that develops COSELA (trilaciclib), an FDA-approved CDK4/6 inhibitor providing myeloprotection for chemotherapy-treated extensive-stage small cell lung cancer patients. The company serves U.S. oncologists and cancer treatment centers, and is a subsidiary of Denmark-based Pharmacosmos Group.
- Ownership category
- akta.pro rank
G1 Therapeutics industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)
Keywords
Where G1 Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Triangle
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
G1 Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- COSELA (Trilaciclib) Sales: Revenue generated from the sale of COSELA (trilaciclib), an FDA-approved drug for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer. The drug is administered intravenously prior to chemotherapy in oncology treatment settings.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
G1 Therapeutics product offering
Product offeringCore offering
G1 Therapeutics develops and commercializes COSELA (trilaciclib), an FDA-approved intravenous CDK4/6 inhibitor administered prior to chemotherapy to reduce the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer. The drug provides transient multilineage myeloprotection by halting hematopoietic stem cell division during cytotoxic treatment while preserving anti-tumor efficacy, and is also being evaluated in additional oncology indications including metastatic triple-negative breast cancer and bladder cancer.
Product overview
G1 Therapeutics is a biopharmaceutical company focused on developing next-generation cancer therapies. The company's portfolio centers on COSELA (trilaciclib), an FDA-approved CDK4/6 inhibitor for myeloprotection during chemotherapy. Trilaciclib is also being evaluated in multiple clinical trials across various cancer indications including bladder cancer (Phase II), triple-negative breast cancer, small cell lung cancer, and colorectal cancer. In August 2024, G1 Therapeutics was acquired by Denmark-based Pharmacosmos Group for approximately $405 million to strengthen Pharmacosmos's oncology supportive care offerings.
Differentiator
Problem solved
Functional benefit
Brands
- COSELA: FDA-approved CDK4/6 inhibitor for myeloprotection in chemotherapy-treated extensive-stage small cell lung cancer patients
Products and services
- COSELA (trilaciclib) COSELA (trilaciclib) is an FDA-approved CDK4/6 inhibitor administered via intravenous infusion prior to chemotherapy. It is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer (ES-SCLC), providing multilineage myeloprotection by transiently halting hematopoietic stem cell division during cytotoxic treatment.
Quantifiable outcome
- Improved overall survival when trilaciclib added to gemcitabine/carboplatin in metastatic triple-negative breast cancer
- +3 more outcomes
Companies that use G1 Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
G1 Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
G1 Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
G1 Therapeutics competitors and assessment
Company assessmentDirect peers
- Coherus BioSciences: Markets UDENYCA and UDENYCA ONBODY, pegfilgrastim biosimilars for chemotherapy-induced neutropenia, directly competing with G-CSF-based supportive care that trilaciclib must displace or complement in community oncology practice.
- Spectrum Pharmaceuticals: Developed and commercialized ROLVEDON (eflapegrastim-xnst), a long-acting G-CSF for chemotherapy-induced neutropenia — a directly adjacent supportive-care mechanism competing for the same oncology budget and prescriber workflow.
- BeyondSpring Pharmaceuticals: Developed plinabulin, a novel non-G-CSF agent intended to prevent chemotherapy-induced neutropenia, representing a mechanistically distinct but indication-overlapping competitor to trilaciclib in CIN/CIM supportive care.
Broad incumbents
- Sandoz: Markets Ziextenzo, a pegfilgrastim biosimilar, and operates a broad oncology-supportive-care portfolio that competes with G1's trilaciclib for the same chemotherapy-induced neutropenia budget at the community oncology level.
- Pfizer: Markets Nyvepria (pegfilgrastim biosimilar) and operates across oncology supportive care; competes with trilaciclib for chemotherapy-induced myelosuppression share through established biosimilar G-CSF alternatives.
- Amgen: Developer of Neulasta (pegfilgrastim) and Neupogen (filgrastim), the dominant G-CSF products used to manage chemotherapy-induced neutropenia — the principal standard-of-care alternative to trilaciclib's myeloprotection approach in ES-SCLC and broader oncology supportive care.
- Viatris: Markets Fulphila, a pegfilgrastim biosimilar, and offers a broad oncology-supportive-care portfolio that competes in the same chemotherapy-induced neutropenia prescribing decisions as trilaciclib.
Emerging players
- Partner Therapeutics: Commercializes Leukine (sargramostim), a GM-CSF used in oncology supportive care, representing an alternative myeloid growth-factor approach that overlaps with trilaciclib's myeloprotection positioning in chemotherapy-treated patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
G1 Therapeutics social profiles
Digital presenceG1 Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
G1 Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
G1 Therapeutics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
G1 Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about G1 Therapeutics
What does G1 Therapeutics do?
G1 Therapeutics develops and commercializes COSELA (trilaciclib), an FDA-approved intravenous CDK4/6 inhibitor administered prior to chemotherapy to reduce the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer. The drug provides transient multilineage myeloprotection by halting hematopoietic stem cell division during cytotoxic treatment while preserving anti-tumor efficacy, and is also being evaluated in additional oncology indications including metastatic triple-negative breast cancer and bladder cancer.
Is G1 Therapeutics a public or private company?
G1 Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was G1 Therapeutics founded?
G1 Therapeutics was founded in 2008. It employs 51 to 100 people.
Where is G1 Therapeutics based?
G1 Therapeutics is headquartered in Triangle, United States, in the North America region.
How does G1 Therapeutics make money?
One revenue line is on record: COSELA (Trilaciclib) Sales.
Who are G1 Therapeutics's main competitors?
Direct peers on record are Coherus BioSciences, Spectrum Pharmaceuticals and BeyondSpring Pharmaceuticals. Broad incumbents are Sandoz, Pfizer, Amgen and Viatris. Partner Therapeutics is listed as an emerging player.
Does G1 Therapeutics have an API?
No public API is recorded for G1 Therapeutics.
What industry is G1 Therapeutics in?
G1 Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAJ, Post-Approval Clinical Development (Phase IV & Lifecycle Management). Its NAICS code is 3254 and its SIC code is 2834.